Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Richard M. Stone, M.D.

Co-Author

This page shows the publications co-authored by Richard Stone and Andrew Brunner.
Connection Strength

1.406
  1. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
    View in: PubMed
    Score: 0.227
  2. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019 02 15; 125(4):541-549.
    View in: PubMed
    Score: 0.211
  3. Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. Am J Hematol. 2018 09; 93(9):1119-1126.
    View in: PubMed
    Score: 0.208
  4. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
    View in: PubMed
    Score: 0.180
  5. Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. Cancer. 2020 Nov 01; 126(21):4735-4743.
    View in: PubMed
    Score: 0.059
  6. Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. Am J Hematol. 2020 03; 95(3):245-250.
    View in: PubMed
    Score: 0.057
  7. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852.
    View in: PubMed
    Score: 0.055
  8. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 08 22; 134(8):678-687.
    View in: PubMed
    Score: 0.055
  9. Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica. 2020 01; 105(1):161-169.
    View in: PubMed
    Score: 0.054
  10. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402.
    View in: PubMed
    Score: 0.054
  11. Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer. 2018 12 15; 124(24):4601-4609.
    View in: PubMed
    Score: 0.052
  12. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254.
    View in: PubMed
    Score: 0.052
  13. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
    View in: PubMed
    Score: 0.051
  14. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
    View in: PubMed
    Score: 0.049
  15. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.